Pages
Products
Support
CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER

Research Resource

Creative Biogene is committed to providing high quality products and services to help scientists around the world find solutions in biological research and drug discovery.

Research Areas

Research of The Role of CLN7 in The Regulation of Lysosomal Function

Research of The Role of CLN7 in The Regulation of Lysosomal Function

Lysosomes play a vital role in eliminating worn-out proteins, damaged organelles, and other unnecessary materials in eukaryotic cells. Dysfunction of lysosomes often leads to lysosomal storage diseases (LSDs), which are characterized by abnormal accumulation of unmetabolized substrates within lysosomes.

Research of Biological Functions and Potential Molecular Mechanisms of TTC9 Gene in Lung Adenocarcinoma

Research of Biological Functions and Potential Molecular Mechanisms of TTC9 Gene in Lung Adenocarcinoma

Lung adenocarcinoma (LUAD) is one of the most commonly diagnosed subtypes of lung cancer, and one of the deadliest cancers. Tetratricopeptide repeat domain 9A (TTC9) is upregulated and has played an oncogenic role in some malignant tumors. However, the expression and role of TTC9 has not yet been elucidated in LUAD.

Research of The Molecular Mechanism of NARF in Promoting Breast Cancer Metastasis

Research of The Molecular Mechanism of NARF in Promoting Breast Cancer Metastasis

Breast cancer is the leading cause of cancer death for women globally, and the vast majority of breast cancer–related deaths are due to metastasis. Advanced breast cancers are characterized by intratumoral hypoxia, which is associated with metastasis, treatment failure, and patient mortality.

HER2 As an Ideal Target for Antibody Drugs

HER2 As an Ideal Target for Antibody Drugs

The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug-the monoclonal antibody trastuzumab-almost 25 years ago.

TMEFF2: A New Target for Multiple Cancers

TMEFF2: A New Target for Multiple Cancers

Transmembrane protein with an EGF-like and two Follistatin-like domains 2 (TMEFF2) is a 374-residue long type-I transmembrane proteoglycan which is proteolytically shed from the cell surface.